Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®

NCT00046371 is registered in ClinicalTrials.gov with Oncothyreon Canada Inc. as lead sponsor.

NCT NCT00046371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®
Lead sponsor
Oncothyreon Canada Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2002
Completion date
August 31, 2005
Enrollment
Not reported
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms